NICE
Novo Nordisk launches Wegovy in the UK
September 4, 2023Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …
Amicus Therapeutics’ Pompe disease treatment approved for use in UK
August 17, 2023Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases
Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …
NICE shares draft guidance for AI’s use in radiotherapy treatment planning
August 14, 2023Research and Development AI, Draft Guidance, NICE, Oncology, radiotherapy
The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine artificial intelligence (AI) technologies which …
AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment
June 9, 2023Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma
UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …
NICE approves first treatment for obstructive HCM for NHS use
June 2, 2023Medical Communications Bristol-Myers Squibb, Cardiology, NHS, NICE, obstructive HCM
The National Institute for Health and Care Excellence (NICE) has announced that it has approved mavacamten (Camzyos) for the treatment …
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
June 2, 2023Medical Communications NHS, NICE, Neurology, Pfizer, migraine
The National Institute for Health and Care Excellence (NICE) has announced that it has recommended an oral treatment for the …
NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus
May 18, 2023Medical Communications Kapruvia, NICE, Nephrology, chronic kidney disease, pruritus
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National Institute for Health and Care …
NICE recommends nine digital treatment options for depression and anxiety
May 17, 2023Medical Communications NICE, Neurology, anxiety, depression, digital health, mental health
The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety …
NICE recommends Hepcludex for NHS use to treat aggressive form of viral hepatitis
May 15, 2023Medical Communications NHS, NICE, Virology, hepatitis
The National Institute for Health and Care Excellence (NICE) has recommended Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta …
NICE recommends Otsuka’s Lupkynis (voclosporin) in combination treatment for active lupus nephritis
May 4, 2023Medical Communications MHRA, NICE, Nephrology, Otsuka Pharmaceuticals, lupus nephritis
Otsuka Pharmaceuticals has announced that the National Institutes for Health and Care Excellence (NICE) has recommended Lupkynis (voclosporin) in combination …
NICE recommends that all women should do pelvic floor exercises
June 29, 2021Manufacturing and Production NHS, NICE, pelvic floor, women's health
NICE has recommended in draft guidance that girls as young as 12 should be encouraged to do pelvic floor muscle …
NICE recommends two new treatments for inflammatory arthritis
June 18, 2021Medical Communications Eli Lilly, NICE, Novartis
NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …
NICE release new guidance on rheumatoid arthritis treatment
June 10, 2021NICE, biosimilar, rheumatoid arthritis
NICE has today published final draft guidance for the treatment of moderate rheumatoid arthritis in patients who have not responded …
New NICE recommendation for Astellas prostate cancer drug
June 8, 2021Manufacturing and Production Astellas, NICE, prostate cancer
A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an …
NICE recommends Janssen’s active psoriatic arthritis drug
May 28, 2021Medical Communications Janssen, NICE, UK, arthritis
NICE have released a Final Appraisal Document (FAD) recommending Janssen’s tremfya (guselkumab) as a new option for treating active psoriatic …
Latest content
FibroFind appoints Lee Borthwick as CEO
